Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines

Sanofi (SNY) will acquire Blueprint Medicines (BPMC) for up to $9.5 billion, sending BPMC shares up 26%. The deal, expected to close in Q3 2025, gives Sanofi access to Ayvakit, a drug for gastrointestinal stromal tumors and systemic mastocytosis, and expands Sanofi's immunology pipeline as it seeks to reduce dependence on Dupixent. Sanofi will pay $129 per share in cash, plus a contingent value right (CVR) tied to the achievement of future development and regulatory milestones for BLU-808.

Analysis

Sanofi's definitive agreement to acquire Blueprint Medicines for a total potential value of up to $9.5 billion signifies a key strategic move to bolster its immunology franchise. The acquisition, priced at $129 per share in cash for BPMC (a 27% premium to its prior closing price) plus non-tradeable contingent value rights (CVRs) linked to BLU-808 milestones amounting to a potential $6 per CVR, prompted an immediate 26% surge in BPMC's shares. Central to the deal is Ayvakit, Blueprint's marketed product for gastrointestinal stromal tumors and systemic mastocytosis, which demonstrated robust growth with $149.4 million in first-quarter 2025 sales (a 61% year-over-year increase) and is projected by Blueprint to achieve $2 billion in sales by 2030. For Sanofi, this acquisition aligns with its strategy to expand its early-stage immunology pipeline, establish itself as a leading immunology company, and reduce its significant reliance on its blockbuster drug Dupixent, which accounted for approximately one-third of Sanofi's total first-quarter 2025 revenues with €3.48 billion in sales. The transaction is anticipated to close in the third quarter of 2025, subject to customary conditions, and Sanofi has clarified that it will not materially impact its 2025 financial guidance.

Key Decisions for Investors

• Blueprint Medicines shareholders should weigh the certainty of the $129 per share cash offer, which reflects a significant premium and has driven a 26% stock increase, against the potential future upside from the CVRs tied to BLU-808 development milestones, considering the transaction's expected Q3 2025 closing.
• Sanofi investors should view this acquisition as a long-term strategic initiative aimed at strengthening its immunology pipeline and diversifying revenue streams away from Dupixent, while noting the company's guidance that the deal will not materially affect 2025 financials.
• Investors should monitor Ayvakit's sales trajectory and new patient starts post-acquisition, as its continued growth is key to realizing the deal's value for Sanofi and achieving Blueprint's $2 billion sales target by 2030.